Evaluating the roles of interleukin-17, C3, C4, antinuclear antibody, and antiphospholipid antibody in the pathophysiology of systemic lupus erythematosus
DOI:
https://doi.org/10.15584/ejcem.2026.2.1Keywords:
antinuclear antibody, antiphospholipid antibody, autoimmunity, complement, interleukin 17, systemic lupus erythematosusAbstract
Introduction and aim. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation, autoantibody (Abs) production, and complement (C) consumption. This study aimed to evaluate the diagnostic and prognostic relevance of antinuclear antibodies (ANA), interleukin (IL)-17A, complement components C3 and C4, and antiphospholipid (APL) Abs in patients to SLE compared with healthy individuals. This study provides an assessment of these biomarkers within a single cohort of an Iraqi population, addressing a regional knowledge gap.
Material and methods. A prospective case–control study was conducted in Al-Nasiriyah, Iraq, from July 2024 to July 2025, including 110 patients with SLE and 70 apparently healthy individuals. Serum levels of ANA, IL-17A, complement C3, complement C4 and APL immunoglobulin (Ig) M and G were measured using enzyme-linked immunosorbent assay (ELISA) and nephelometry. Statistical analyzes were included using descriptive statistics, chi-square tests, t-tests, and correlation analyses.
Results. Patients with SLE showed significantly higher levels of ANA, IL-17A, and APL Abs, along with significantly lower levels of complement C3 and C4. ANA was positively correlated with IL-17A and APL Abs and negatively with complement components. There were also significant negative correlations of APL-IgM/IgG with C3 and C4, while IL-17A did not show a correlation with C3 or C4.
Conclusion. These findings demonstrate coordinated immune activation and complement depletion in SLE and emphasize the value of combined biomarker evaluation within a context of a population of the Middle East specifically.
Downloads
References
Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393(10188):2344-2358. doi:10.1016/S0140-6736(19)30546-X
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi:10.1002/art.34473
Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1647-1656. doi:10.1002/art.24568
Yang Y, Yan C, Yu L, et al. The star target in SLE: IL-17. Inflamm Res. 2022;72(2):313-328. doi:10.1007/s00011-022-01674-z
Dossybayeva K, Bexeitov Y, Mukusheva Z, et al. Analysis of peripheral blood basophils in pediatric systemic lupus erythematosus. Diagnostics. 2022;12(7):1701. doi:10.3390/diagnostics12071701
Sekine A, Wada T, Sawa N, et al. T-cell receptor CRαβ⁺ CD4⁻ CD8⁻ (double-negative) T cells may predict pathological kidney findings in patients with suspected lupus nephritis. Nephron. 2025;149(12):701-708. doi:10.1159/000547797
Pratama MZ, Handono K, Kalim H, et al. Association of the CD28 markers with the disease activity in systemic lupus erythematosus patients. F1000Research. 2023;12:1362. doi:10.12688/f1000research.140890.1
Barguil Macêdo M, Wahadat MJ, Björk A, et al. Anti-mitochondrial antibodies as markers of disease activity in childhood-onset systemic lupus erythematosus: a longitudinal cohort study. Rheumatology (Oxford). 2025;64(9):5096-5100. doi:10.1093/rheumatology/keaf275
Tarr T, Dérfalvi B, Győri N, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus. 2015;24(8):796-803. doi:10.1177/0961203314563817
Ayano M, Horiuchi T. Complement as a biomarker for systemic lupus erythematosus. Biomolecules. 2023;13(2):367. doi:10.3390/biom13020367
Pisetsky DS, Lipsky PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020;16(10):565-579. doi:10.1038/s41584-020-0480-7
Tektonidou MG, Andreoli L, Limper M, et al. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open. 2019;5(1):e000924. doi:10.1136/rmdopen-2019-000924
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412. doi:10.1002/art.40930
Choi MY, Clarke AE, St Pierre Y, et al. Antinuclear antibody–negative systemic lupus erythematosus in an international inception cohort. Arthritis Care Res (Hoboken). 2019;71(7):893-902. doi:10.1002/acr.23712
Yang Y, Yan C, Yu L, et al. The star target in SLE: IL-17. Inflamm Res. 2023;72(2):313-328. doi:10.1007/s00011-022-01674-z
Akhter S, Tasnin FM, Islam MN, et al. Role of Th17 and IL-17 cytokines on inflammatory and autoimmune diseases. Curr Pharm Des. 2023;29(26):2078-2090. doi:10.2174/1381612829666230904150808
Peliçari KD, Postal M, Sinicato NA, et al. Serum interleukin-17 levels are associated with nephritis in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo). 2015;70(5):313-317. doi:10.6061/clinics/2015;70(5):313-317
Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol. 2017;13(9):538-547. doi:10.1038/nrrheum.2017.125
Gandino IJ, Scolnik M, Bertiller E, et al. Complement levels and risk of organ involvement in patients with systemic lupus erythematosus. Lupus Sci Med. 2017;4(1):e000209. doi:10.1136/lupus-2017-000209
Takamatsu R, Shimojima Y, Kishida D, et al. The impact of normal serum complement levels on the disease classification and clinical characteristics in systemic lupus erythematosus. Adv Rheumatol. 2022;62(1):49. doi:10.1186/s42358-022-00283-y
Hisada R, Atsumi T. An antiphospholipid antibody profile as a biomarker for thrombophilia in systemic lupus erythematosus. Biomolecules. 2023;13(4):617. doi:10.3390/biom13040617
González-Treviño M, Figueroa-Parra G, Yang JX, et al. Association between antiphospholipid antibodies and diffuse alveolar haemorrhage risk in systemic lupus erythematosus: a systematic review and meta-analysis. Rheumatology (Oxford). 2025;64(4):1598-1608. doi:10.1093/rheumatology/keae632
Farina N, Abdulsalam R, McDonnell T, et al. Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events. Rheumatology (Oxford). 2023;62(6):2252-2256. doi:10.1093/rheumatology/keac596
Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2015;3(2):75. doi:10.5152/eurjrheum.2015.0085
Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: from discovery to targeting. Trends Mol Med. 2016;22(3):230-241. doi:10.1016/j.molmed.2016.01.001
Ebrahimi Chaharom F, Ebrahimi AA, Feghhi Koochebagh F, et al. Association of IL-17 serum levels with clinical findings and systemic lupus erythematosus disease activity index. Immunol Med. 2023;46(4):175-181. doi:10.1080/25785826.2023.2202050
Rana RS, Naik B, Yadav M, et al. Serum complements and immunoglobulin profiles in systemic lupus erythematosus patients: an observational study at a teaching hospital. J Family Med Prim Care. 2022;11(2):608-613. doi:10.4103/jfmpc.jfmpc_960_21
Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11(7):928. doi:10.3390/biom11070928
Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two–week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016-1027. doi:10.1002/art.40049
Lazzaroni MG, Fredi M, Andreoli L, et al. Triple antiphospholipid (aPL) antibodies positivity is associated with pregnancy complications in aPL carriers: a multicenter study on 62 pregnancies. Front Immunol. 2019;10:1948. doi:10.3389/fimmu.2019.01948
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213
Chaturvedi S, Brodsky RA, McCrae KR. Complement in the pathophysiology of the antiphospholipid syndrome. Front Immunol. 2019;10:438. doi:10.3389/fimmu.2019.00449
Jakiela B, Iwaniec T, Plutecka H, et al. Signs of impaired immunoregulation and enhanced effector T-cell responses in the primary antiphospholipid syndrome. Lupus. 2016;25(4):389-398. doi:10.1177/0961203315618267
Raymond W, Ostli-Eilertsen G, Griffiths S, et al. IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: evidence for a dual role. Eur J Rheumatol. 2017;4(1):29. doi:10.5152/eurjrheum.2017.16059
Weinstein A, Alexander RV, Zack DJ. A review of complement activation in SLE. Curr Rheumatol Rep. 2021;23:19. doi:10.1007/s11926-021-00984
Fanouriakis A, Kostopoulou M, Andersen J, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi:10.1136/ard-2023-224762
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
